Search

Your search keyword '"Cerinic, Marco Matucci"' showing total 20 results
Start Over Author "Cerinic, Marco Matucci" Publication Year Range Last 3 years
20 results on '"Cerinic, Marco Matucci"'

1. Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysis

Author

Wyss, Anja, Jordan, Suzana, Graf, Nicole, Carreira, Patricia E., Distler, Jörg, Cerinic, Marco Matucci, Siegert, Elise, Henes, Jörg, Zanatta, Elisabetta, Riccieri, Valeria, Truchetet, Marie-Elise, Oksel, Fahrettin, Li, Mengtao, Kucharz, Eugene J., Eyerich, Kilian, Del Galdo, Francesco, Vonk, Madelon C., Vold, Anna-Maria Hoffman, Gabrielli, Armando, and Distler, Oliver

Published
2024
Full Text
View/download PDF

3. Switching from rituximab originator to GP2013 or CT-P10 biosimilars in autoimmune rheumatic diseases: drug retention rate and safety data from a multicentric retrospective cohort.

Author

Gentileschi, Stefano, Bruni, Cosimo, Gaggiano, Carla, D'Alessandro, Roberto, Pacini, Giovanni, Sota, Jurgen, Guiducci, Serena, Cerinic, Marco Matucci, and Frediani, Bruno

Subjects
PROPORTIONAL hazards models, RHEUMATISM, LOG-rank test, IMMUNOSUPPRESSIVE agents, AUTOIMMUNE diseases, NEUROLEPTIC malignant syndrome
Abstract

Background: Real-world evidence supporting a safe and effective transition from rituximab originator (RTX-O) to its biosimilars (RTX-B) in autoimmune rheumatic diseases (ARDs) is still limited. Objectives: The primary aims of this study were to evaluate the long-term persistence of RTX-B after the non-medical switch (NMS) from RTX-O in ARD patients, and to explore the RTX-B safety profile. The secondary aims were to evaluate the impact of different factors on RTX-B drug retention rate (DRR) and to identify any factors associated with RTX-B discontinuation. Design: Retrospective observational study. Methods: We included consecutive ARD patients undergoing NMS from RTX-O to GP2013 or CT-P10 from January 2018 to December 2020. RTX-B DRR was estimated by Kaplan–Meier plot analysis and compared according to different factors by the Log-rank test; the Cox proportional hazard model was used to detect factors associated with RTX-B discontinuation in the first 36 months. Results: We enrolled 181 patients switching to RTX-B: GP2013 in 143 (79.0%) cases and CT-P10 in 38 (21.0%). The estimated DRR for RTX-B was 81.5% at 12 months, 80.6% at 24 months, and 77.4% at 36 months. The incidence of adverse events with RTX-B was 12.6/100 patients/year. In the Log-rank test, no statistically significant differences were observed in the RTX-B DRR according to sex (p = 0.171), ARD diagnosis (p = 0.281), and concomitant immunosuppressive therapy (p = 0.054); on the contrary, patients on GP2013 showed a higher DRR than those on CT-P10 (p < 0.001). In the Cox proportional hazard analysis, the switch to CT-P10 was associated with a higher probability of stopping treatment (hazard ratio, 1.83 (confidence interval, 1.10–3.04), p = 0.02). Conclusion: NMS to RTX-B is associated with a high chance of retaining the drug for up to 36 months, irrespective of the diagnosis. GP2013 showed a higher retention rate than CT-P10. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. P130 Unmet needs and treatment preferences concerning digital ulcers in patients with systemic sclerosis

Author

Bandini, Giulia, primary, Alunno, Alessia, additional, Ruaro, Barbara, additional, Galetti, Ilaria, additional, Alcacer-Pitarch, Begonya, additional, Oliveira Pinheiro, Filipe, additional, Campanaro, Giulia, additional, Jade, Judith, additional, Muir, Lindsay, additional, Pignone, Alberto Moggi, additional, McMahan, Zsuzsanna H, additional, Aoufy, Khadija El, additional, Cerinic, Marco Matucci, additional, and Hughes, Michael, additional

Published
2024
Full Text
View/download PDF

5. P137 A multinational survey to identify the clinicians perspectives concerning proton pump inhibitors in patients with systemic sclerosis

Author

Bandini, Giulia, primary, Alunno, Alessia, additional, Oliveira Pinheiro, Filipe, additional, Campochiaro, Corrado, additional, Galetti, Ilaria, additional, Cerinic, Pietro Matucci, additional, Ruaro, Barbara, additional, Pignone, Alberto Moggi, additional, Dagna, Lorenzo, additional, Cerinic, Marco Matucci, additional, McMahan, Zsuzsanna H, additional, and Hughes, Michael, additional

Published
2024
Full Text
View/download PDF

6. Utility of bronchoalveolar lavage for COVID-19: a perspective from the Dragon consortium

Author

Tomassetti, Sara, primary, Ciani, Luca, additional, Luzzi, Valentina, additional, Gori, Leonardo, additional, Trigiani, Marco, additional, Giuntoli, Leonardo, additional, Lavorini, Federico, additional, Poletti, Venerino, additional, Ravaglia, Claudia, additional, Torrego, Alfons, additional, Maldonado, Fabien, additional, Lentz, Robert, additional, Annunziato, Francesco, additional, Maggi, Laura, additional, Rossolini, Gian Maria, additional, Pollini, Simona, additional, Para, Ombretta, additional, Ciurleo, Greta, additional, Casini, Alessandro, additional, Rasero, Laura, additional, Bartoloni, Alessandro, additional, Spinicci, Michele, additional, Munavvar, Mohammed, additional, Gasparini, Stefano, additional, Comin, Camilla, additional, Cerinic, Marco Matucci, additional, Peired, Anna, additional, Henket, Monique, additional, Ernst, Benoit, additional, Louis, Renaud, additional, Corhay, Jean-louis, additional, Nardi, Cosimo, additional, and Guiot, Julien, additional

Published
2024
Full Text
View/download PDF

7. Bone Marrow Edema: Overview of Etiology and Treatment Strategies

Author

Tarantino, Umberto, Greggi, Chiara, Cariati, Ida, Caldora, Patrizio, Capanna, Rodolfo, Capone, Antonio, Civinini, Roberto, Colagrande, Stefano, De Biase, Pietro, Falez, Francesco, Iolascon, Giovanni, Maraghelli, Davide, Masi, Laura, Cerinic, Marco Matucci, Sessa, Giuseppe, and Brandi, Maria L.

Published
2022
Full Text
View/download PDF

8. The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort

Author

Bellando-Randone, Silvia, primary, Wilhalme, Holly, additional, Bruni, Cosimo, additional, Czirjak, Laszlo, additional, Distler, Oliver, additional, Allanore, Yannick, additional, Cuomo, Giovanna, additional, Denton, Christopher, additional, Galdo, Francesco Del, additional, Gheorghiu, Ana M., additional, RICCIERI, VALERIA, additional, Walker, Ulrich, additional, Truchet, Marie Elise, additional, Vonk, Madelon C., additional, Foeldvari, Ivan, additional, Cerinic, Marco Matucci, additional, and Furst, Daniel E., additional

Published
2024
Full Text
View/download PDF

11. Clinical implications of interstitial pneumonia with autoimmune features diagnostic criteria in idiopathic pulmonary fibrosis: A case control study

Author

Tomassetti, Sara, primary, Ravaglia, Claudia, additional, Puglisi, Silvia, additional, Wells, Athol U., additional, Ryu, Jay H., additional, Bosi, Marcello, additional, Dubini, Alessandra, additional, Piciucchi, Sara, additional, Girelli, Francesco, additional, Parronchi, Paola, additional, Lavorini, Federico, additional, Rosi, Elisabetta, additional, Luzzi, Valentina, additional, Cerinic, Marco Matucci, additional, and Poletti, Venerino, additional

Published
2023
Full Text
View/download PDF

12. Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from EUSTAR cohort

Author

Zanatta, Elisabetta, Huscher, Dörte, Ortolan, Augusta, Avouac, Jérôme, Airó, Paolo, Balbir-Gurman, Alexandra, Siegert, Elise, Cerinic, Marco Matucci, Cozzi, Franco, Riemekasten, Gabriela, Hoffmann-Vold, Anna-Maria, Distler, Oliver, Gabrielli, Armando, Heitmann, Stefan, Hunzelmann, Nicolas, Montecucco, Carlomaurizio, Morovic-Vergles, Jadranka, Ribi, Camillo, Doria, Andrea, Allanore, Yannick, EUSTAR collaborators, and University of Zurich

Subjects
10051 Rheumatology Clinic and Institute of Physical Medicine, 610 Medicine & health
Published
2022
Full Text
View/download PDF

14. Utility of bronchoalveolar lavage for COVID-19: a perspective from the Dragon consortium.

Author

Tomassetti, Sara, primary, Ciani, Luca, additional, Luzzi, Valentina, additional, Gori, Leonardo, additional, Giuntoli, Leonardo, additional, Lavorini, Federico, additional, Poletti, Venerino, additional, Ravaglia, Claudia, additional, Torrego, Alfons, additional, Maldonado, Fabien, additional, Lentz, Robert, additional, Annunziato, Francesco, additional, Maggi, Laura, additional, Rossolini, Gian Maria, additional, Pollini, Simona, additional, Para, Ombretta, additional, Ciurleo, Greta, additional, Casini, Alessandro, additional, Rasero, Laura, additional, Bartoloni, Alessandro, additional, Spinicci, Michele, additional, Munavvar, Mohammed, additional, Gasparini, Stefano, additional, Comin, Camilla, additional, Cerinic, Marco Matucci, additional, Peired, Anna, additional, Henket, Monique, additional, Benoit, Ernst, additional, Louis, Renaud, additional, Corhay, Jean-Louis, additional, Nardi, Cosimo, additional, and Guiot, Julien, additional

Published
2022
Full Text
View/download PDF

17. Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort

Author

Zanatta, Elisabetta, Huscher, Doerte, Ortolan, Augusta, Avouac, Jerome, Airo, Paolo, Balbir-Gurman, Alexandra, Siegert, Elise, Cerinic, Marco Matucci, Cozzi, Franco, Riemekasten, Gabriela, Hoffmann-Vold, Anna-Maria, Distler, Oliver, Gabrielli, Armando, Heitmann, Stefan, Hunzelmann, Nicolas, Montecucco, Carlomaurizio, Morovic-Vergles, Jadranka, Ribi, Camillo, Doria, Andrea, Allanore, Yannick, Zanatta, Elisabetta, Huscher, Doerte, Ortolan, Augusta, Avouac, Jerome, Airo, Paolo, Balbir-Gurman, Alexandra, Siegert, Elise, Cerinic, Marco Matucci, Cozzi, Franco, Riemekasten, Gabriela, Hoffmann-Vold, Anna-Maria, Distler, Oliver, Gabrielli, Armando, Heitmann, Stefan, Hunzelmann, Nicolas, Montecucco, Carlomaurizio, Morovic-Vergles, Jadranka, Ribi, Camillo, Doria, Andrea, and Allanore, Yannick

Abstract

Objectives To characterize patients with positive anti-topoisomerase I (ATA) in lcSSc. Methods SSc patients enrolled in the EUSTAR cohort with a disease duration of <= 3 years at database entry were considered. We assessed the risk of major organ involvement in the following groups: ATA-lcSSc vs ACA-lcSSc and vs ANA without specificity (ANA)-lcSSc, and ATA-lcSSc vs ATA-dcSSc. Cox regression models with time-dependent covariates were performed with the following outcomes: new-onset interstitial lung disease (ILD), ILD progression [forced vital capacity (FVC) decline >= 10% and >= 5% vs values at ILD diagnosis), primary myocardial involvement (PMI), pulmonary hypertension (PH), any organ involvement and all-cause mortality. Results We included 1252 patients [194 ATA-lcSSc (15.5%)], with 7.7 years (s.d. 3.5) of follow-up. ILD risk was higher in ATA-lcSSc vs ACA- and ANA-lcSSc and similar to ATA-dcSSc, although with less frequent restrictive lung disease. The risk of FVC decline >= 10% (35% of ATA-lcSSc) was lower in ATA-lcSSc than in ATA-dcSSc, whereas FVC decline >= 5% occurs similarly between ATA-lcSSc (58% of patients) and other SSc subsets, including ATA-dcSSc. The risk of PMI was similar in ATA-lcSSc and ANA-lcSSc but lower than in ACA-lcSSc; no difference in PH and mortality risk was observed among lcSSc subsets. The risk of any organ involvement, PMI and PH was lower and the mortality tended to be lower in ATA-lcSSc vs ATA-dcSSc. Conclusion ATA-lcSSc patients have a high risk of ILD, albeit with a lower risk of progression compared with ATA-dcSSc, supporting careful screening for ILD in this subgroup.

Published
2022

18. Menstruation-Related Disorders—Dysmenorrhea and Heavy Bleeding—as Significant Epiphenomena in Women With Rheumatic Diseases

Author

Orlandi, Martina, primary, Vannuccini, Silvia, additional, El Aoufy, Khadija, additional, Melis, Maria Ramona, additional, Lepri, Gemma, additional, Sambataro, Gianluca, additional, Bellando-Randone, Silvia, additional, Guiducci, Serena, additional, Cerinic, Marco Matucci, additional, and Petraglia, Felice, additional

Published
2022
Full Text
View/download PDF

20. Bone Marrow Edema: Overview of Etiology and Treatment Strategies

Author

Marco Matucci Cerinic, Ida Cariati, Francesco Falez, Roberto Civinini, Rodolfo Capanna, Chiara Greggi, Antonio Capone, Stefano Colagrande, Giuseppe Sessa, Giovanni Iolascon, Laura Masi, Pietro De Biase, Davide Maraghelli, Umberto Tarantino, P. Caldora, Maria Luisa Brandi, Tarantino, Umberto, Greggi, Chiara, Cariati, Ida, Caldora, Patrizio, Capanna, Rodolfo, Capone, Antonio, Civinini, Roberto, Colagrande, Stefano, De Biase, Pietro, Falez, Francesco, Iolascon, Giovanni, Maraghelli, Davide, Masi, Laura, Cerinic, Marco Matucci, Sessa, Giuseppe, and Brandi, Maria L

Subjects
medicine.medical_specialty, medicine.diagnostic_test, business.industry, Magnetic resonance imaging, General Medicine, Gold standard (test), Bone marrow edema, Magnetic Resonance Imaging, Diagnosis, Differential, Settore MED/33, Surgical therapy, medicine, Etiology, Physical modalities, Treatment strategy, Edema, Humans, Orthopedics and Sports Medicine, Surgery, Radiology, business, Bone Marrow Diseases
Abstract

➤ Bone marrow edema (BME) is a nonspecific but relevant finding, usually indicating the presence of an underlying pathology. ➤ The gold standard technique for detecting BME is magnetic resonance imaging (MRI), as it allows for a correct diagnosis to be made, which is extremely important given the heterogeneity of BME-related diseases. ➤ Depending on the severity of painful symptomatology and the MRI evidence, different treatment strategies can be followed: physical modalities, pharmacological options, and surgical therapy.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results